SOX plus sintilimab vs P-SOX vs SOX as neoadjuvant therapy in advanced gastric cancer: Efficacy and safety

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

2977

Figures (1-6)

149

Tables (1-4)

137

Sum=3283

Publishing Process of This Article

Item

Count

Browse

Download

Sum=12

Aug 15, 2025 (publication date) through Aug 29, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Aug 15, 2025; 17(8): 109646
Published online Aug 15, 2025. doi: 10.4251/wjgo.v17.i8.109646

Full Size Figure Download Figure

Figure 4 Calibration curve for progression-free survival. A: Training set; B: Validation set. PFS: Progression-free survival.

Citation: Wang YC, Zhang CG, Wang YW, Guo C, Pan T, Yu PJ, Cai BJ, Ding RH, Qiang JL, Deng CQ, Hu CH, Xu YH. SOX plus sintilimab vs P-SOX vs SOX as neoadjuvant therapy in advanced gastric cancer: Efficacy and safety. World J Gastrointest Oncol 2025; 17(8): 109646
URL: https://www.wjgnet.com/1948-5204/full/v17/i8/109646.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i8.109646